The mechanisms of action of Tumor Treating Fields

Justin C. Moser; Ellaine Salvador; Karina Deniz; Kenneth Swanson; Jack Tusynski; Kristen W. Carlson; Narasimha Kumar Karanam; Chirag B. Patel; Michael Story; Emil Lou; Carsten Hagemann

doi:10.1158/0008-5472.can-22-0887

The mechanisms of action of Tumor Treating Fields

Justin C. Moser, Ellaine Salvador, Karina Deniz, Kenneth Swanson, Jack Tusynski, Kristen W. Carlson, Narasimha Kumar Karanam, Chirag B. Patel, Michael Story, Emil Lou, Carsten Hagemann

Research output: Contribution to journal › Review article › peer-review

65 Scopus citations

Abstract

Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under study in many other cancer types. While antimitotic effects were the first recognized biological anticancer activity of TTFields, data have shown that tumor treating fields achieve their anticancer effects through multiple mechanisms of action. TTFields therefore have the ability to be useful for many cancer types in combination with many different treatment modalities. Here, we review the current understanding of TTFields and their mechanisms of action.

Original language	English (US)
Pages (from-to)	3650-3658
Number of pages	9
Journal	Cancer Research
Volume	82
Issue number	20
DOIs	https://doi.org/10.1158/0008-5472.can-22-0887
State	Published - Oct 15 2022

Bibliographical note

Funding Information:
J. Moser reports other support from Novocure during the conduct of the study; personal fees from BMS, Amunix, Thirona Bio, Adagene, and Imaging Endpoints; other support from Novocure, Genentech, Alpine Immune Sciences, Amgen, Trishula Therapeutics, BioEclipse Therapeutics, FujiFilm, ImmunSensor, Simcha, Repertiore Immune Sciences, Nektar Therapeutics, Synthorx Inc., from Istari Oncology, Ideaya Biosciences, Rubius Therapeutics, University of Arziona, and Senwha Biosciences; personal fees from Caris Life Sciences, Daiichi-Sankyo, TGen, and Immunocore outside the submitted work. E. Salvador reports grants from Novocure Ltd. during the conduct of the study. K.D. Swanson reports grants and other support from Novocure

Publisher Copyright:
© 2022 The Authors; Published by the American Association for Cancer Research.

PubMed: MeSH publication types

Journal Article
Review
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/0008-5472.can-22-0887License: CC BY-NC-ND

Find It

Find It at U of M Libraries

Cite this

@article{10b1fed92cbe456d9e7cae2fbf32a7a7,

title = "The mechanisms of action of Tumor Treating Fields",

abstract = "Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under study in many other cancer types. While antimitotic effects were the first recognized biological anticancer activity of TTFields, data have shown that tumor treating fields achieve their anticancer effects through multiple mechanisms of action. TTFields therefore have the ability to be useful for many cancer types in combination with many different treatment modalities. Here, we review the current understanding of TTFields and their mechanisms of action.",

author = "Moser, {Justin C.} and Ellaine Salvador and Karina Deniz and Kenneth Swanson and Jack Tusynski and Carlson, {Kristen W.} and Karanam, {Narasimha Kumar} and Patel, {Chirag B.} and Michael Story and Emil Lou and Carsten Hagemann",

note = "Funding Information: J. Moser reports other support from Novocure during the conduct of the study; personal fees from BMS, Amunix, Thirona Bio, Adagene, and Imaging Endpoints; other support from Novocure, Genentech, Alpine Immune Sciences, Amgen, Trishula Therapeutics, BioEclipse Therapeutics, FujiFilm, ImmunSensor, Simcha, Repertiore Immune Sciences, Nektar Therapeutics, Synthorx Inc., from Istari Oncology, Ideaya Biosciences, Rubius Therapeutics, University of Arziona, and Senwha Biosciences; personal fees from Caris Life Sciences, Daiichi-Sankyo, TGen, and Immunocore outside the submitted work. E. Salvador reports grants from Novocure Ltd. during the conduct of the study. K.D. Swanson reports grants and other support from Novocure Publisher Copyright: {\textcopyright} 2022 The Authors; Published by the American Association for Cancer Research.",

year = "2022",

month = oct,

day = "15",

doi = "10.1158/0008-5472.can-22-0887",

language = "English (US)",

volume = "82",

pages = "3650--3658",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - The mechanisms of action of Tumor Treating Fields

AU - Moser, Justin C.

AU - Salvador, Ellaine

AU - Deniz, Karina

AU - Swanson, Kenneth

AU - Tusynski, Jack

AU - Carlson, Kristen W.

AU - Karanam, Narasimha Kumar

AU - Patel, Chirag B.

AU - Story, Michael

AU - Lou, Emil

AU - Hagemann, Carsten

N1 - Funding Information: J. Moser reports other support from Novocure during the conduct of the study; personal fees from BMS, Amunix, Thirona Bio, Adagene, and Imaging Endpoints; other support from Novocure, Genentech, Alpine Immune Sciences, Amgen, Trishula Therapeutics, BioEclipse Therapeutics, FujiFilm, ImmunSensor, Simcha, Repertiore Immune Sciences, Nektar Therapeutics, Synthorx Inc., from Istari Oncology, Ideaya Biosciences, Rubius Therapeutics, University of Arziona, and Senwha Biosciences; personal fees from Caris Life Sciences, Daiichi-Sankyo, TGen, and Immunocore outside the submitted work. E. Salvador reports grants from Novocure Ltd. during the conduct of the study. K.D. Swanson reports grants and other support from Novocure Publisher Copyright: © 2022 The Authors; Published by the American Association for Cancer Research.

PY - 2022/10/15

Y1 - 2022/10/15

N2 - Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under study in many other cancer types. While antimitotic effects were the first recognized biological anticancer activity of TTFields, data have shown that tumor treating fields achieve their anticancer effects through multiple mechanisms of action. TTFields therefore have the ability to be useful for many cancer types in combination with many different treatment modalities. Here, we review the current understanding of TTFields and their mechanisms of action.

AB - Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under study in many other cancer types. While antimitotic effects were the first recognized biological anticancer activity of TTFields, data have shown that tumor treating fields achieve their anticancer effects through multiple mechanisms of action. TTFields therefore have the ability to be useful for many cancer types in combination with many different treatment modalities. Here, we review the current understanding of TTFields and their mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=85140143930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140143930&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.can-22-0887

DO - 10.1158/0008-5472.can-22-0887

M3 - Review article

C2 - 35839284

SN - 0008-5472

VL - 82

SP - 3650

EP - 3658

JO - Cancer Research

JF - Cancer Research

IS - 20

ER -

The mechanisms of action of Tumor Treating Fields

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this